Non Conventional Approaches for Management of Drug Addiction and CNS Disorders

Ahmed Shaker Ali; Samar Faisal A Miski

Authors

Ahmed Shaker Ali
Samar Faisal A Miski

Keywords:

addiction, natural psychedelics, hallucinogens

Abstract

Addiction is a serious and widespread disorder that has devastating consequences for individuals and society. However, the existing treatment for addiction is moderately effective at best. In recent years, the researchers have renewed their interest in the effectiveness of classic hallucinogens for clinical uses such as treating addictions and other behavior-related health issues. In the present work, we tried to review both pharmacological mechanisms of actions and the recent researches done on the use of classical hallucinogens in treating addiction. Also, some selective review related to other relevant researches was done, for suggesting prospectus of future research. The classic hallucinogen showed extraordinary record for safety in clinical research. Also, with the limited understanding of the clinically important impacts of classic hallucinogens, there are many opportunities for future research which may contribute novel knowledge and help in treating addiction. This review provides the scientific literature related to the use of classic hallucinogens and the related mechanism of action of psychedelic in treating drug addiction.

Downloads

How to Cite

Non Conventional Approaches for Management of Drug Addiction and CNS Disorders. (2020). Global Journal of Medical Research, 20(B7), 35-39. https://medicalresearchjournal.org/index.php/GJMR/article/view/2263

Download Citation

References

C O'brien (2017) Drug Use Disorders and Addiction, in Goodman & Gilman's: The Pharmacological Basis of Therapeutics.

Michael Bogenschutz, Matthew Johnson (2016) Classic hallucinogens in the treatment of addictions. 64, 250-258.

George Koob, Denise Kandel, Ruben Baler, Nora Volkow (2015) Pathophysiology of Addiction. 1, 359-381.

C Lüscher (2017) Drugs of Abuse, in Basic &amp. 14.

Evan Kyzar, Charles Nichols, Raul Gainetdinov, David Nichols, Allan Kalueff (2017) Psychedelic Drugs in Biomedicine. 38(11), 992-1005.

Simon Gibbons, Warunya Arunotayanun (2013) Natural Product (Fungal and Herbal) Novel Psychoactive Substances. 345-362.

S Brandt, T Passie (2012) Research on psychedelic substances. 4(7-8), 539-542.

K Tupper (2015) Psychedelic medicine: a reemerging therapeutic paradigm. 187(14), 1054-1059.

A Oliveira-Lima, R Santos, A Hollais, C Gerardi-Junior, M Baldaia, R Wuo-Silva, T Yokoyama, J Costa, E Malpezzi-Marinho, P Ribeiro-Barbosa, L Berro, R Frussa-Filho, E Marinho (2015) Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice. 142, 28-36.

Feyza Aricioglu, Hale Altunbas (2003) Harmane Induces Anxiolysis and Antidepressant‐Like Effects in Rats. 1009(1), 196-201.

Aline Pic-Taylor, Luciana Da Motta, Juliana De Morais, Willian Junior, Alana Santos, Leandro Campos, Marcia Mortari, Marcus Von Zuben, Eloisa Caldas (2015) Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. 118, 102-110.

Elisabet Domínguez-Clavé, Joaquim Soler, Matilde Elices, Juan Pascual, Enrique Álvarez, Mario De La Fuente Revenga, Pablo Friedlander, Amanda Feilding, Jordi Riba (2016) Ayahuasca: Pharmacology, neuroscience and therapeutic potential. 126(Pt 1), 89-101.

Ede Frecska, Petra Bokor, Michael Winkelman (2016) The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. 7, 35.

M Belgers, M Leenaars, J Homberg, M Ritskes-Hoitinga, A Schellekens, C Hooijmans (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis. 6(5), e826-e826.

Marieke Henstra, Liza Wong, Abdel Chahbouni, Noortje Swart, Cor Allaart, Ferdi Sombogaard (2017) Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. 55(6), 600-602.

Deborah Mash, Linda Duque, Bryan Page, Kathleen Allen-Ferdinand (2018) Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. 9, 529.

S Farrow (2018) Cytochrome P450 and Omethyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga. 293(36), 13821-13833.

Lena Rubi, Daniel Eckert, Stefan Boehm, Karlheinz Hilber, Xaver Koenig (2017) Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. 17(2), 215-218.

B Simonson (2015) Pharmacology and antiaddiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. 172(2), 515-531.

Nicole Crowley, Thomas Kash (2015) Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. 62, 51-60.

M Jakaria, Duk-Yeon Cho, M Ezazul Haque, Govindarajan Karthivashan, In-Su Kim, Palanivel Ganesan, Dong-Kug Choi (2018) Neuropharmacological Potential and Delivery Prospects of Thymoquinone for Neurological Disorders. 2018(1).

N Md Fauzi (2018) Potential therapeutic effects of thymoquinone on treatment of amphetamine abuse. 8, 187.

M Johnson, W Richards, R Griffiths (2008) Human hallucinogen research: guidelines for safety. 22(6), 603-620.

William Fantegrossi, Kevin Murnane, Chad Reissig (2008) The behavioral pharmacology of hallucinogens. 75(1), 17-33.